Literature DB >> 11545624

Analysis of urinary prostacyclin and thromboxane/prostacyclin ratio in patients with rheumatoid arthritis using gas chromatography/selected ion monitoring.

T Hishinuma1, H Nakamura, T Sawai, T Mitomo, H Inoue, F Matsumoto, M Mizugaki.   

Abstract

We investigated production of prostacyclin and the urinary ratio of thromboxane and prostacyclin in patients with rheumatoid arthritis. The prostacyclin production level was assessed according to the level of urinary 2,3-dinor-6-keto-prostaglandin F(1 alpha)measuring by gas chromatography/selected ion monitoring. In patients receiving medication, the prostacyclin level was lower and the thromboxane/prostacyclin ratio was greater compare with that of healthy volunteers. The prostacyclin level in patients without medication was approximately 4-fold higher than that of healthy volunteers and 8-fold higher than those of medicated groups. Although the ratio of the group without medication was similar to that of healthy volunteers, the urinary levels of each prostanoid were higher than those of other groups. Then, the ratios of groups receiving steroids were higher than that of other groups owing to high TX level. The present findings demonstrated that endogenous prostacyclin and thromboxane production increased in patients without medication, and prostacyclin production decreased with medication. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11545624     DOI: 10.1054/plef.2001.0293

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  2 in total

1.  Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors.

Authors:  Peter B Anning; Barbara Coles; Jonathan Morton; Haibin Wang; Jashim Uddin; Jason D Morrow; Sudhansu K Dey; Lawrence J Marnett; Valerie B O'Donnell
Journal:  Blood       Date:  2006-08-24       Impact factor: 22.113

Review 2.  Persisting eicosanoid pathways in rheumatic diseases.

Authors:  Marina Korotkova; Per-Johan Jakobsson
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.